Randomised controlled trial
Cold Laser vs Excimer Laser in Lower Limb Atherosclerosis
- Randomised controlled trial
- prospective
- multicentre
- non-inferiority
Authors' conclusion
The 355-nm CLA system showed similar safety and efficacy to the excimer laser, with a trend toward reducing TLR in complex PAD lesions.
Study context
- Population
- Symptomatic lower extremity peripheral artery disease (PAD) (Rutherford classes 2–5) with ≥70% stenosis or occlusion109 analysed
- Participants
- 110 participants
- Comparison
- Cold laser atherectomy (CLA) vs excimer laser atherectomy (ELA)
- CLAn = 58
- ELAn = 51reference
- Primary endpoint
- Improvement in vessel diameter stenosis (DS%) prior to any adjunctive therapy
Primary result
As reported in the abstract
Postprocedural DS%
Postprocedural DS% CLA 59.92% (SD 15.02%) · ELA 57.52% (SD 17.22%)
Mean improvement in DS%
- CLA vs ELA: P = 0.438 — no significant intergroup difference
Secondary outcomes
Primary patency · 30 days
TLR · 30 days
Primary patency · 6 months
TLR · 6 months
P = 0.698
Ankle-brachial index and Rutherford classification
- Improved similarly in the 2 groups
Target lesion revascularization (TLR) in TASC C/D and long lesions (≥10 cm) (subgroup) · 6 months
- Lower TLR with CLA
- P < 0.05
Original publication
Cold Laser vs Excimer Laser in Lower Limb Atherosclerosis. JACC Cardiovasc Interv. Published 27 April 2026. doi:10.1016/j.jcin.2026.02.036
Summarised from the published abstract; every number is checked against it